Top 20 Series-Rank 11-AstraZeneca acquires global diabetic business

AstraZeneca strengthens its India distributor partnership


Organization: AstraZeneca Pharma India Ltd
MD: Mr Sanjay Murdeshwar
Bioscience Revenue: Rs 468.13 crore


AstraZeneca (AZ) Pharma India reported total business of Rs 468.13 crore for the 12-month period ending March 31, 2015. AZ registered six percent growth in bioscience revenue. The primary business here includes manufacture and sale of pharma products, clinical trial services, and copromotional services. AZ rendered co-promotion services for pharmaceutical products to Bristol Myers Squibb (BMS) India till January 31, 2014. AstraZeneca group companies also acquired the global diabetic business of BMS.

Consequent to the aforesaid acquisition, AZ has entered into a consignment sale agreement with BMS and accordingly sale of diabetic products by BMS in India for the period February 1, 2014 to March 31,2014, has been included as part of the sales of the company.
AZ and Dr Reddy's Laboratories (DRL) entered into a distribution agreement for two drugs namely, Riax and Riax-M. The drugs' trademarks are with AstraZeneca group. DRL will distribute the two drugs in the country.

It also announced its collaboration with Sun Pharmaceutical Industries in June 2015. They entered into a distribution services agreement for AZ's brand ‘Axcer', a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS) in India.

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email